Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Permanent Puerto Rico tax credit

This article was originally published in The Gray Sheet

Executive Summary

Permanent Puerto Rico tax credit: Targeted wage-based credit for companies doing business in Puerto Rico would be made permanent unless certain economic goals were met under legislation (S 906) introduced June 16 by Sens. Alfonse D'Amato (R-N.Y.), John Chafee (R-R.I.), John Breaux (D-La.), Orrin Hatch (R-Utah) and Bob Graham (D-Fla.). Sec. 30a of the tax code would also be expanded to cover companies seeking to locate or expand their activities in Puerto Rico. Sec. 30a was established in the 104th Congress' phase-out of the Sec. 936 tax credit for economic activities in Puerto Rico and other territories that limited the credit to companies already claiming wage-based 936 credit. Both wage-based and income-based credits would be eliminated after Jan. 1, 2006 under current law...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT008279

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel